Biomarkers for assessing the efficacy of immune checkpoint inhibitor (ICI) therapies have been actively investigated in many cancer types and include tumor-infiltrating lymphocyte (TIL) counts, intratumor programmed cell death-1 (PD-1)/PD-L1 expression, and tumor mutation burden [6,7]. Here, PDCD1 is linked to neoplasm.